Provided herein are methods for treating coronavirus diseases. In one embodiment, the method comprises administering to a coronavirus disease patient a therapeutic amount of decidua stromal cells. In one embodiment, the method comprises administering to the subject a therapeutic amount of decidua stromal cells (DSCs). In some embodiments, the coronavirus disease is SARS, MERS or COVID-19. The method of the disclosure can be used to treat a subject who has acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or both.

Formulations and methods for activating signaling molecules outside a native physiological response are provided. The formulations can include an activator component and a signaling component containing both signaling molecules and mesenchymal stem cells. When a formulation containing both an activator component and a signaling component is injected into or applied to a treatment area, the activator component may activate the signaling molecules of the signaling component which in turn signal the mesenchymal stem cells of the signaling component to regrow, repair or otherwise provide a benefit to the treatment area.

Formulations and methods for activating signaling molecules outside a native physiological response are provided. The formulations can include an activator component and a signaling component containing both signaling molecules and mesenchymal stem cells. When a formulation containing both an activator component and a signaling component is injected into or applied to a treatment area, the activator component may activate the signaling molecules of the signaling component which in turn signal the mesenchymal stem cells of the signaling component to regrow, repair or otherwise provide a benefit to the treatment area.

The problem that differences among lots in components and amounts of growth factors and the like in platelet-rich plasmas derived from an autologous plasma and the freeze-dried preparations thereof are large, and the effects of the lots are not kept constant is solved.

Specifically, a freeze-dried preparation comprising megakaryocytes and platelets induced to differentiate from stem cells, a pharmaceutical composition comprising the freeze-dried preparation, and the like are provided.

The problem that differences among lots in components and amounts of growth factors and the like in platelet-rich plasmas derived from an autologous plasma and the freeze-dried preparations thereof are large, and the effects of the lots are not kept constant is solved.

Specifically, a freeze-dried preparation comprising megakaryocytes and platelets induced to differentiate from stem cells, a pharmaceutical composition comprising the freeze-dried preparation, and the like are provided.

The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.

The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.

Disclosed herein are nucleic acid constructs that can be used to build genetic circuits for producing antibodies comprising split toxins. Also disclosed herein are methods of producing platelets comprising the antibodies. The platelets produced by the methods disclosed herein can be used to target circulating tumor cells.

Disclosed herein are nucleic acid constructs that can be used to build genetic circuits for producing antibodies comprising split toxins. Also disclosed herein are methods of producing platelets comprising the antibodies. The platelets produced by the methods disclosed herein can be used to target circulating tumor cells.

Disclosed are compounds and compositions for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. Also disclosed herein are methods for storing platelets and methods for improving platelet survival upon transfusion with one or more compounds or compositions as described herein.